Zespól żyly glównej górnej u chorych na raka pluca – rola radioterapii
Abstract
Author(s): Elà ¼bieta Plula, Pawel Blecharz, Marian Reinfuss, Tomasz Walasek, Magdalena PÃÂcak, Marta Rogowska
Evaluation of efficacy, complications and prognostic factors in patients with lung cancer, suffering from superior vena cava syndrome (SVCS) is presented in the paper. Literature analysis shows that complete or partial remission of the symptoms is observed in 70-95% of patients. In 50-70% of patients the remission is observed in the first 2 weeks of irradiation. Complication rates is acceptable - in 26-50% of patients authors observe mild or moderate oesophagitis, 8-10% of patients suffer from transient nausea and vomiting. Literature review shows median overall survival rate oscillating from 12 to 40 weeks, twelve-month survival rate - from 20 to 25% and 5-year survival rate - from 2 to 5%. The only recognized prognostic factor for symptoms remission in lung cancer patients with SVCS is histological type of cancer. Complete remission of SVCS is observed in 78% of patients with small cell lung cancer, however only in 63% of patients with non-small cell lung cancer.
<Share this article
Editors List
-
Prof. Elhadi Miskeen
Obstetrics and Gynaecology Faculty of Medicine, University of Bisha, Saudi Arabia
-
Ahmed Hussien Alshewered
University of Basrah College of Medicine, Iraq
-
Sudhakar Tummala
Department of Electronics and Communication Engineering SRM University – AP, Andhra Pradesh
-
Alphonse Laya
Supervisor of Biochemistry Lab and PhD. students of Faculty of Science, Department of Chemistry and Department of Chemis
-
Fava Maria Giovanna
Onkologia i Radioterapia peer review process verified at publons
Indexed In
- Directory of Open Access Journals
- Scimago
- SCOPUS
- EBSCO A-Z
- MIAR
- Euro Pub
- Google Scholar
- Medical Project Poland
- PUBMED
- Cancer Index
- Gdansk University of Technology, Ministry Points 20